Lyell Immunopharma, Inc. (LYEL)
12.26
-0.62
(-4.81%)
USD |
NASDAQ |
Sep 10, 15:23
Lyell Immunopharma Gross Profit Margin (Quarterly) : -55.45K% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -55.45K% |
| March 31, 2026 | -116.5K% |
| December 31, 2025 | -39.85K% |
| September 30, 2025 | -17.01K% |
| June 30, 2025 | -39.09K% |
| March 31, 2025 | -49.06K% |
| December 31, 2024 | -45.59K% |
| September 30, 2024 | -13.66K% |
| June 30, 2024 | -37.60K% |
| March 31, 2024 | -167.4K% |
| December 31, 2023 | -38.80K% |
| September 30, 2023 | -20.32K% |
| June 30, 2023 | -16.71K% |
| Date | Value |
|---|---|
| March 31, 2023 | -7.63K% |
| December 31, 2022 | 90.51% |
| September 30, 2022 | -139.0K% |
| June 30, 2022 | 89.56% |
| March 31, 2022 | -618.4% |
| December 31, 2021 | -41.39% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | -22.62% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -89.79% |
| Return on Assets | -69.20% |
| Return on Invested Capital | -76.23% |
| Profit Margin (Quarterly) | -1.12M% |
| Operating Margin (Quarterly) | -1.23M% |
| Return on Net Operating Assets | -450.7% |